Benzonatate (Tessalon Perles) Dosing
For adults and children over 10 years: the standard dose is 100-200 mg three times daily as needed for cough, with a maximum of 600 mg per day in three divided doses 1.
Dosing by Age Group
Adults and Children ≥10 Years
- Usual dose: 100-200 mg orally three times daily (TID) as needed
- Maximum daily dose: 600 mg in three divided doses
- Maximum single dose: 200 mg 1
Children Under 10 Years
- Contraindicated: Safety and effectiveness have not been established in children below age 10 1
- Fatal overdoses have been reported in children under 10, with death occurring within 1 hour of accidental ingestion 1, 2
Critical Safety Considerations
Administration Requirements
Capsules must be swallowed whole—never broken, chewed, dissolved, cut, or crushed 1. Release of benzonatate in the mouth produces temporary local anesthesia of oral mucosa and can cause choking 1.
Overdose Risk Profile
The evidence reveals benzonatate has a narrow therapeutic window with rapid, life-threatening toxicity:
- Onset of symptoms: 15-20 minutes after ingestion 1
- Death reported: Within 1 hour of overdose 1
- Serious outcomes occur at doses ≥200 mg in overdose settings 3
- Toxicity manifestations: Seizures, cardiac arrest, ventricular dysrhythmias, torsades de pointes, coma, and asystole 3, 4, 5
Research data from poison center surveillance (2000-2019) showed that while unintentional exposures rarely caused serious toxicity, intentional exposures resulted in serious adverse effects in 22% of cases, with a 0.8% mortality rate 6. Notably, all fatalities involved cardiac dysrhythmias rather than seizures 3.
Storage and Patient Counseling
- Keep out of reach of children at all times 1
- If numbness or tingling of tongue, mouth, throat, or face occurs, refrain from eating or drinking until resolved 1
- Never double dose if a dose is missed—skip it and take the next scheduled dose 1
Clinical Context
While benzonatate appears in guideline tables for cough management in specific populations (lung cancer patients), it is listed as a last-line option for opioid-resistant cough that has failed peripheral antitussives 7. The 2017 CHEST guideline positions it alongside nebulized local anesthetics as a trial therapy when other pharmacologic approaches have failed 7.
Common Pitfalls to Avoid
- Never prescribe to children under 10 years—this is an absolute contraindication due to fatal overdose risk
- Never instruct patients to chew or dissolve capsules for faster effect
- Do not exceed 600 mg daily or 200 mg per single dose
- Warn patients explicitly about keeping medication away from children, as even small ingestions can be fatal
The evidence base for benzonatate's effectiveness is remarkably weak—a 2023 systematic review found that initial clinical studies had very small populations, limited settings, and would not meet current regulatory standards 8. Despite this, prescriptions increased 52% from 2004-2009 2, highlighting a disconnect between evidence quality and clinical use.